NCT02074657View on ClinicalTrials.gov

"LANK-2: Activated and Expanded NK Cell Immunotherapy Together With Salvage Chemotherapy in Children, Adolescents and Young Adults With Relapsed or Refractary Acute Leukemia"

PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

September 30, 2016

Study Completion Date

September 30, 2016

Conditions
Relapsed/Refractory Paediatric Acute Leukaemia
Interventions
BIOLOGICAL

Activated and expanded natural killer cells (NKAEs)

Activated and expanded natural killer cells (NKAEs) from haploidentical donor

Trial Locations (2)

28041

Hospital 12 de Octubre, Madrid

28046

Hospital Infantil Universitario La Paz, Madrid

All Listed Sponsors
lead

Hospital Universitario La Paz

OTHER

NCT02074657 - "LANK-2: Activated and Expanded NK Cell Immunotherapy Together With Salvage Chemotherapy in Children, Adolescents and Young Adults With Relapsed or Refractary Acute Leukemia" | Biotech Hunter | Biotech Hunter